Effect of Human IgG Antiphospholipid Antibodies on an In Vivo Thrombosis Model in Mice

Summary

High levels of IgG antiphospholipid antibodies (aPL) have been associated with clinical thrombosis. It is uncertain however whether these antibodies play a direct role in thrombosis or are merely epiphenomena. To investigate whether antiphospholipid antibodies might play a role in thrombosis, we utilized a novel mouse model in which the dynamics of in vivo thrombosis can be studied. CD1 mice (26-30 g) were passively immunized with 25 mg of human IgG from a patient with the Antiphospholipid Syndrome (IgG-APS) (n = 17), IgG from normal pooled sera (TgG-NHS) (n = 9). or saline solution (n = 17), followed by 40 mg of the same preparations at 48 h. At 72 h, levels of human aPL antibodies, detected using the anticardiolipin ELISA test (aCL ELISA test), in mice immunized with IgG-APS, were 50-100 GPL units. Each animal was anesthetized, femoral vein minimally mobilized and subjected to a standardized “pinch” injury to induce thrombosis. The vessel was transilluminated using acrylic optical fibers connected to a light source, and clot formation and dissolution were visualized by a standard surgical microscope equipped with a video camera, video recorder, and computer assisted analysis system. Results showed that average clot size was significantly larger in mice immunized with IgG-APS compared to those treated with saline (p <0.037). In addition, the thrombus persisted longer in a significantly higher number of mice immunized with IgG-APS (10/17) compared to mice immunized with IgG-NHS (1/9) or saline (2/12) (p <0.02). These data suggest that IgG-APS may play a role in thrombus formation in humans. In addition, this study shows the feasibility of using this in vivo murine thrombus model for study of the effects of aPL antibodies.

• References

• 1 Harris EN. Syndrome of the Black Swan. Br J Haematol 1987; 26: 324-6
• 2 Hughes GRV, Hams EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-9
• 3 Asherson RA. A “primary” antiphospholipid syndrome?. J Rheumatol 1988; 15: 1742-6
• 4 Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome. J Rheumatol 1989; 16: 482-8
• 5 Harris EN, Chan JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetal loss, thrombocytopenia: predictive value of IgG anticardiolipin antibodies. Arch Intern Med 1986; 146: 2153-9
• 6 Alving BM, Barr CF, Tang BD. Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am J Med 1990; 88: 112-6
• 7 Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. Am J Obstet Gynecol 1989; 160: 439-43
• 8 Loizou S, Byion MA, Englert HR, Walporl MJ, Hughes GRV. Association of quantitative anti-cardiolipin antibody levels with fetal loss. Q J Med 1988; 68: 525-31
• 9 Alarcon-Segovia D, Deleze M, Orai CV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine 1990; 68: 353-65
• 10 Boey ML, Calaco CB, Gharavi AE. Thrombosis in SLE: striking association with the presence of circulating “lupus anticoagulant”. Br Med J. 1983; 287: 1021-3
• 11 Elias M, Eldor A. Thromboembolism in patients with the “lupus-like” circulating anticoagulant. Arch Intern Med 1984; 144: 510-5
• 12 Branch WD. Immunologic disease and fetal death. Clin Obstet Gynecology 1987; 30: 295-311
• 13 Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Lupus anticoagulant in pregnancy. Br J Obstet Gynaecol 1984; 91: 357-63
• 14 Branch DW, Dudley DJ, Mitchell MD, Creightari KA, Abott IM, Hammond EH, Daynes RA. Immunoglobulin G fractions from patients with antiphospholipid antibodies caused fetal death in Balb/c mice: a model for autoimmune fetal loss. Am J Obstet Gynecol 1990; 163: 210-6
• 15 Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anticardiolipin antibodies. Proc Natl Acad Sci (USA) 1991; 88: 3069-73
• 16 Mendlovic S, Brocke S, Shoenfeld Y, Ben Bassat M, Meshorer A, Bakimer R, Mozes E. Induction of a systemic lupus erythematosus-like disease by a common human antiDNA idiotype. Proc Natl Acad Sci (USA) 1988; 85: 2260-4
• 17 Bakimer R, Fishman P, Blank M, Srednc B, Djaidetti M, Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody. J Clin Invest 1992; 89: 1558-63
• 18 Sthoeger ZM, Tartakovsky B, Bentwich Z, Mozes E. Monoclonal anticardiolipin antibodies derived from mice with experimental lupus erythematosus: characterization and the induction of a secondary antiphospholipid syndrome. I Clin Immunol 1993; 13: 127-38
• 19 Fishman P, Falach-Vaknine E, Zigelman Rosa, Bakimer R, Sredni B, Djaletti M, Shoenfeld Y. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 91: 1834-7
• 20 Gharavi AE. Anti-phospholipid syndrome in murine lupus. In: Phospholipid binding antibodies. Harris EN, Exner T, Asherson RA, Hughes GRV. (eds) CRC Press; Boca Raton: 1991: 403-16
• 21 Smith HR, Hansen CL, Rose R, Canoso RT. Autoimmune MRL-lpr/lpr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol 1990; 17: 911-5
• 22 Weir DM. (ed) Handbook of Experimental Immunology vol: I. Immunochemistry. Blackwell Sci Publ. Oxford: 1973
• 23 Harris EN. Annotation: antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
• 24 Stockmans F, Deckinyn H, Gruwez J, Vemiylen J, Aclund R. Continuous quantitative monitoring of mural thrombus kinetics in the crushed rat femoral vein. Thromb Haemost 1991; 65: 425-31
• 25 Comp PC, De Baukt LE, Esmon NL, Esmon CT. Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants (abstract). Blood 1983; 62: 299a
• 26 Freyssinet JM, Wiesel ML, Gauchy J, Boneu B, Cazenave IP. An IgM lupus anticoagulant that reutilizes the enhancing effect of phospholipid on purified thrombomodulin activity. A mechanism for thrombosis. Thromb Haemost 1986; 55: 309-13
• 27 Cariou R, Tobelin G, Bellucci S, Soria J. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells inhibition of thrombomodulin dependent protein C activation. Thromb Haemost 1988; 60: 54-8
• 28 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32
• 29 Brandt JT. Assays for phospholipid-dependent formation of thrombin and Xa: a potential method for quantifying lupus anticoagulant activity. Thromb Haemost 1991; 66: 453-8
• 30 Galli M, Beguin S, Lindhout T, Hemker CH. Inhibition of phospholipid and platelet dependent prothrombinase activity in the plasma of patients with lupus anticoagulants. Am J Haematol 1989; 72: 549-55
• 31 Galli M, Comfurius P. Maasen et al Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein co-factor. Lancet 1990; 336: 1547-50
• 32 Mc Neil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipidbinding inhibitor of coagulation: β₂ glycoprotein 1 (apolipoprotein H). Proc Natl Acad Sci (USA) 1990; 87: 4120-4